Volume - 13 | Issue-1
Volume - 13 | Issue-1
Volume - 13 | Issue-1
Volume - 13 | Issue-1
Volume - 13 | Issue-1
Although the benefits of sodium glucose cotransporter 2 inhibitors (SGLT2i) on cardiovascular events have been reported in patients with heart failure (HF), the impact of SGLT2i on cardiac remodelling remains to be established.